How to buy Enanta Pharmaceuticals stock - 18 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Enanta Pharmaceuticals stock

Own Enanta Pharmaceuticals stock in just a few minutes.

Enanta Pharmaceuticals, Inc is a biotechnology business based in the US. Enanta Pharmaceuticals shares (ENTA) are listed on the NASDAQ and all prices are listed in US Dollars. Enanta Pharmaceuticals employs 141 staff and has a trailing 12-month revenue of around USD0.00.

How to buy shares in Enanta Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Enanta Pharmaceuticals. Find the stock by name or ticker symbol: ENTA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Enanta Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Enanta Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Enanta Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Enanta Pharmaceuticals share price

Use our graph to track the performance of ENTA stocks over time.

Enanta Pharmaceuticals shares at a glance

Information last updated 2021-04-15.
52-week rangeUSD$40.32 - USD$58.59
50-day moving average USD$50.3743
200-day moving average USD$47.0018
Wall St. target priceUSD$68.14
PE ratio 436.7
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.119

Buy Enanta Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Enanta Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Enanta Pharmaceuticals under- or over-valued?

Valuing Enanta Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Enanta Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Enanta Pharmaceuticals's P/E ratio

Enanta Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 437x. In other words, Enanta Pharmaceuticals shares trade at around 437x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Enanta Pharmaceuticals's EBITDA

Enanta Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$14.8 million.

The EBITDA is a measure of a Enanta Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Enanta Pharmaceuticals financials

Revenue TTM USD$101.6 million
Gross profit TTM USD$122.5 million
Return on assets TTM -8.42%
Return on equity TTM -12.4%
Profit margin -57%
Book value $22.44
Market capitalisation USD$1.1 billion

TTM: trailing 12 months

Shorting Enanta Pharmaceuticals shares

There are currently 2.2 million Enanta Pharmaceuticals shares held short by investors – that's known as Enanta Pharmaceuticals's "short interest". This figure is 1.6% up from 2.2 million last month.

There are a few different ways that this level of interest in shorting Enanta Pharmaceuticals shares can be evaluated.

Enanta Pharmaceuticals's "short interest ratio" (SIR)

Enanta Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Enanta Pharmaceuticals shares currently shorted divided by the average quantity of Enanta Pharmaceuticals shares traded daily (recently around 165519.38392186). Enanta Pharmaceuticals's SIR currently stands at 13.31. In other words for every 100,000 Enanta Pharmaceuticals shares traded daily on the market, roughly 13310 shares are currently held short.

However Enanta Pharmaceuticals's short interest can also be evaluated against the total number of Enanta Pharmaceuticals shares, or, against the total number of tradable Enanta Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Enanta Pharmaceuticals's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Enanta Pharmaceuticals shares in existence, roughly 110 shares are currently held short) or 0.1388% of the tradable shares (for every 100,000 tradable Enanta Pharmaceuticals shares, roughly 139 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Enanta Pharmaceuticals.

Find out more about how you can short Enanta Pharmaceuticals stock.

Enanta Pharmaceuticals share dividends

We're not expecting Enanta Pharmaceuticals to pay a dividend over the next 12 months.

Enanta Pharmaceuticals share price volatility

Over the last 12 months, Enanta Pharmaceuticals's shares have ranged in value from as little as $40.32 up to $58.59. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Enanta Pharmaceuticals's is 0.4004. This would suggest that Enanta Pharmaceuticals's shares are less volatile than average (for this exchange).

Enanta Pharmaceuticals overview

Enanta Pharmaceuticals, Inc. , a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site